114 related articles for article (PubMed ID: 23051894)
1. BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
Goussetis DJ; Gounaris E; Platanias LC
Autophagy; 2013 Jan; 9(1):93-4. PubMed ID: 23051894
[TBL] [Abstract][Full Text] [Related]
2. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Goussetis DJ; Gounaris E; Wu EJ; Vakana E; Sharma B; Bogyo M; Altman JK; Platanias LC
Blood; 2012 Oct; 120(17):3555-62. PubMed ID: 22898604
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Wu EJ; Goussetis DJ; Beauchamp E; Kosciuczuk EM; Altman JK; Eklund EA; Platanias LC
Cancer Biol Ther; 2014 Apr; 15(4):473-8. PubMed ID: 24496081
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL/p62/SQSTM1: a cannibal embrace.
Auberger P
Blood; 2012 Oct; 120(17):3389-90. PubMed ID: 23100300
[TBL] [Abstract][Full Text] [Related]
5. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
7. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Koyama D; Kikuchi J; Kuroda Y; Ohta M; Furukawa Y
Cancer Sci; 2021 Jan; 112(1):194-204. PubMed ID: 33070465
[TBL] [Abstract][Full Text] [Related]
8. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
9. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.
Helgason GV; Karvela M; Holyoake TL
Blood; 2011 Aug; 118(8):2035-43. PubMed ID: 21693757
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Yoon P; Giafis N; Smith J; Mears H; Katsoulidis E; Sassano A; Altman J; Redig AJ; Tallman MS; Platanias LC
Mol Cancer Ther; 2006 Nov; 5(11):2815-23. PubMed ID: 17121928
[TBL] [Abstract][Full Text] [Related]
11. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
Goussetis DJ; Altman JK; Glaser H; McNeer JL; Tallman MS; Platanias LC
J Biol Chem; 2010 Sep; 285(39):29989-97. PubMed ID: 20656687
[TBL] [Abstract][Full Text] [Related]
12. MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation.
Colecchia D; Rossi M; Sasdelli F; Sanzone S; Strambi A; Chiariello M
Autophagy; 2015; 11(10):1790-802. PubMed ID: 26291129
[TBL] [Abstract][Full Text] [Related]
13. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
[TBL] [Abstract][Full Text] [Related]
14. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
16. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.
Krause DS; Lazarides K; Lewis JB; von Andrian UH; Van Etten RA
Blood; 2014 Feb; 123(9):1361-71. PubMed ID: 24394666
[TBL] [Abstract][Full Text] [Related]
17. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
18. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
